Advertisement
Journal of Investigative Dermatology Home

Society for Investigative Dermatology 2020 Board of Directors Meeting Minutes

    Published:October 05, 2021DOI:https://doi.org/10.1016/j.jid.2021.09.011
        The Society for Investigative Dermatology
        13 May 2020
        Held via Zoom Meeting
        Present: Richard Gallo, MD/PhD, Nicole Ward, PhD, Ponciano Cruz, MD, Mark S. Udey, MD/PhD, Mitchell Denning, PhD, Sarah Millar, PhD, Maryam Asgari, MD, Matthew Vesely, MD/PhD, Janet Fairley, MD, Paul Nghiem, MD/PhD, Heidi Jacobe, MD, Allison Billi, MD/PhD, JP Therrien, PhD, Sam Hwang, MD/PhD, Valentina Greco, PhD, Luis Garza, MD/PhD, Maria Morasso, PhD, Suephy Chen, MD, Robert Swerlick, MD, Natasha Hill, PhD, Jim Rumsey, Becky Minnillo, DM/MPA, and Elizabeth Blalock.
        Ponciano Cruz, MD, Society for Investigative Dermatology (SID) President, called the meeting to order and welcomed the members to the virtual meeting. A motion to approve the meeting minutes from the fall 2019 Board meeting in Chicago was made, seconded, and approved. He then asked the Board if anyone had any conflict-of-interest declarations to make or amend. Dr. Hwang reported a recent relationship that would not conflict with Board business and that he would complete the online form in June when the SID office sends it out.
        Dr. Cruz provided a brief review of the President’s report, indicating that the majority of the material contained in the report would be covered at various points of the Board meeting.

         Journal

        Mark Udey, MD/PhD, Journal of Investigative Dermatology (JID) editor, gave the Board an update regarding Journal activities. He shared that the COVID-19 stay at home directives had at least one positive consequence, in that it had rendered the editorial board more accessible.
        He does anticipate a decrease in submitted material for the remainder of 2020. Efforts will be made to accommodate any shortages in published content, including the publication of a special issue on “Aging,” and lessening Editorial Board requests for nonessential experiments from authors.
        In addition, there will be two supplements later in 2020, including a National Alopecia Areata Foundation symposium proceedings and a special European Society for Dermatological Research (ESDR) 50th anniversary issue.
        The Journal has been utilizing a consultant, Morna Conway, PhD, to guide the development of strategies and goals, including enhancing the reviews program, launching the new open access (OA) journal, and strengthening the impact factor. Based on discussions held during the fall strategy meeting, the JID has also recruited three new social media editors.
        Dr. Udey also reviewed the current acceptance rate, days to final decision, publication statistics, opt-in OA figures, JID connector, and Research Techniques Made Simple activity.

         Governance

        Dr. Cruz called for a review of reports from standing and ad-hoc committees.
        Becky Minnillo, DM/MPA, presented the list of 384 new SID members (most due to bundling SID attendees) that had been approved by the committee on membership was reviewed. A motion to approve the entire slate was made, seconded, and approved. It was suggested that the committee be tasked with collecting data on the virtual meeting format and developing an updated list of member benefits for future recruitment purposes.
        Dr. Minnillo pointed out the drastic reduction of member renewals for the 2020 dues cycle, due to institutional restrictions and the lack of an in-person meeting as an incentive. She posed the possibility of considering an extension of membership expiration in order to maintain the current royalty split. Dr. Gallo offered a suggestion to confer with the ESDR to see if they would be open to maintaining the current split (as in 2019) for 2020, as they are likely in the same predicament with the cancellation of their fall meeting in Amsterdam.
        Nicole Ward, PhD, Deputy Secretary-Treasurer, reviewed the process for the search for an editor for the new JID Gold publication set to launch. A total of three candidates were interviewed, and the Committee recommends the appointment of Russell Hall, MD, to the inaugural position.
        Richard Gallo, MD/PhD, Secretary-Treasurer, reviewed the recently revised process of electing directors. The finalists from the online voting for two new directors were Daniel Kaplan, MD, PhD, and Andrzej Dlugosz, MD. They were unanimously approved by the Board. They will be ratified via a vote of members present at the SID business meeting on Friday 15 May.
        Dr. Gallo described the activities of the Secretary-Treasurer search committee. A call for nominations was sent out in the fall of 2019, and four candidates submitted full proposals by the February 2020 deadline. Three finalists were identified and interviewed via Zoom on 11 May. After discussion, the committee recommends Paul Nghiem, MD, PhD, as the next Deputy Secretary-Treasurer. A motion to approve Dr. Nghiem was made, seconded, and approved. His appointment will be ratified via a vote of members present at the SID business meeting on Friday 15 May.
        As a result of the selection of Dr. Nghiem as the next Deputy Secretary-Treasurer, a vacancy was created on the Board until 2023, when his term would have ended. It was suggested that Niroshana Anandasabapathy, MD, PhD, be appointed, as she had the next highest votes for director in the online voting. A motion to approve Dr. Anandasabapathy was made, seconded, and approved. Dr. Ward offered to reach out to see if she would accept and would inform her that she would be eligible for reappointment.

         Educational Programs

        Jim Rumsey, SID Chief Operating Officer, reviewed the 2020 meeting abstract statistics, various sessions and lectures that would be included live in the virtual meeting programming, and those that would be prerecorded and available for on-demand viewing. He also provided updates on future meeting sites through 2025. He mentioned that the Westin Kierland would like to have the SID meeting return in a future year.
        Dr. Minnillo reviewed the utilization of the Zoom technology platform to broadcast the live sessions, and to prerecord all the named lectures for on-demand viewing. She had received over 100 of the concurrent oral presentations and embedded the hyperlinks to the videos in each of the 16 concurrent minisymposia program pages. These will be posted for viewing on 14 May. She also provided current registration figures for the live sessions: there were 2,005 registered for 14 May; 1,833 for 15 May; and 1,685 for 16 May.

         Finance

        Mr. Rumsey provided an overview of fiscal year (FY) 2019 final figures, including a significant surplus of over $320K. He explained that the impressive surplus was a mix of increases in major revenue streams including educational grants and sponsorship, and reductions in several expense categories. He also reviewed the revised FY2020 year-to-date projections due to the cancellation of the Scottsdale meeting. He was able to greatly reduce the corresponding live meeting expenses and secured nearly $140K PPP forgivable loan from the government for payroll support. In addition, some limited annual meeting grants were approved, resulting in a projected surplus of over $50K. The Board members commented that this is rather remarkable, given that the variance to the original approved budget was only $15K (original surplus was $65K).

         Development/Fundraising

        Dr. Minnillo gave the Board updates on 2020 fundraising progress to date; efforts focused on salvaging Continuing Medical Education grants for the virtual meeting. Most of the grant requests were denied due to COVID-19 impact of canceling live meetings. As a result, the $125,000 secured fell very short of the overall $350,000 budgeted annual meeting goal. The SUN Pharma support was renewed for $350,000, and a total of $37,000 was approved for the retreat. Overall, a total of $537K was raised to an approved FY2020 budget of $800K, or 67%.

         Outreach

        Dr. Gallo briefly reviewed recent activity of the International SID (ISID), including plans for an upcoming virtual Board meeting. The report from the MDS was also referenced for the management services provided by the SID office.

         Other

        The Board met in an executive session.
        With no further business to discuss, a motion to adjourn was made, seconded, and unanimously approved.
        Prepared by Becky Minnillo on 28 May 2020.
        Society for Investigative Dermatology 2020 Board of Directors Meeting Minutes
        The Society for Investigative Dermatology
        October 20, 2020
        Held via Zoom Meeting
        Present: Janet Fairley, MD, Nicole Ward, PhD, Suephy Chen, MD, Sam Hwang, MD/PhD, Maria Morasso, PhD, Andrew Kowalczyk, PhD, Lisa Beck, MD, Andrzej Dlugosz, MD, Allison Billi, MD/PhD, Luis Garza, MD/PhD, Maryam Asgari, MD, Sewon Kang, MD, Jean-Philippe Therrien, PhD, Paul Nghiem, MD/PhD, Mark S. Udey, MD/PhD, Daniel Kaplan, MD/PhD, Heidi Jacobe, MD, Niroshana Anandasabapathy, MD/PhD, and Natasha Hill, PhD
        Invited Guests: Terri Monturano (Elsevier) and Russell Hall, MD (Editor, JID Innovations)
        Staff: Jim Rumsey, Becky Minnillo, DM/MPA, and Elizabeth Blalock
        Unable to Attend: Ponciano Cruz, MD
        President Janet Fairley called the meeting to order and welcomed the Board. A motion to approve the meeting minutes from the virtual May SID Board meeting was made, seconded, and approved.
        COI: Dr. Fairley asked Board members if anyone had any conflict-of-interest declarations to make or amend—none were stated.
        Dr. Fairley provided a brief review of the President’s report, which summarized the deliberations of recent executive committee calls. She indicated that most of the material contained in the report would be covered at various points of the Board meeting.

         Journal

        Journal Editor, Mark Udey, provided an overview of the Editor’s report for the group. He relayed that the COVID pandemic did not seem to have a negative impact on the Journal. The impact factor (IF) for 2019 was 7.143, up a full point from 2018. In order to continue to generate highly cited papers, more Review and Perspectives articles would be solicited. In addition, a special “Aging” issue is scheduled to be published in 2021.
        Other topics discussed included the production schedule, review times, selection of the new social media editors, publication statistics, and updates on the Journal of Investigative Dermatology (JID) Connector and Research Techniques Made Simple, and updates on manuscript submission statistics. Fast track submission was deployed with the goal of publication within 1 month of submission, which was felt to have increased the IF. Additional discussion focused on considering whether reviewers might be reviewed either by authors, or other reviewers.
        Invited Guest, Terri Monturano from Elsevier Publishing, provided an overview of the publisher’s report. She shared details of factors that led to the increased IF. A mere two articles on atopic dermatitis generated nearly 200 citations each. Original articles are the number one contributor to IF, providing the top 75 citations, with Letters to the Editor following as the second. Clinical Reviews are the most influential manuscripts, with Immunology and Infection close behind. She went on to share that the JID Innovations (JIDI) submission portal had opened on 28 September. Some Board members expressed concern that authors may have pressure from their institution to publish only in high IF publications.
        Invited Guest, Russell Hall, JIDI editor, provided an overview of the recent launch of the new publication. The pressure from big funding entities such as Howard Hughes Medical Institute and Wellcome Trust is a strong incentive to publish in a purely open access journal, some are prohibiting submitting to a hybrid.
        The scope is intentionally broad and will have an emphasis on methodology. It will follow the high standards of the JID and will be able to disseminate the articles very quickly. Dr. Hall also pointed out that including negative studies is also important. Reproducibility is a problem, and negative studies can help address it. They identify gaps and can stimulate additional avenues of investigation.
        Authors who submit a manuscript to the JID will be asked if they are willing to be considered for JIDI if triaged. The Editorial Board will also solicit review and encourage de novo submissions. Once JIDI published its first 25 articles, it can be indexed.
        Marketing and submissions sites are open and ready for the debut issue. At this early stage, the JIDI needs advocates to inform potential authors and readers that it will strive to be innovative, inclusive, and interdisciplinary. It will take time to establish its reputation, but all agreed it is an excellent start. Some startup publications waived submission fees to hasten the compilation of the first 25 articles.

         Governance

        The informational reports from standing committees—membership, education, scientific programs—were briefly reviewed.
        Vice-President Andrew Kowalczyk reviewed the audit committee report with the Board. Discussions ensued regarding the contents of the report and the recommendations made by the auditing firm. A motion was made to approve the report. The motion was seconded and unanimously approved.
        The Board reviewed the report from the committee on nominations, who provided a slate of potential Board Officers for 2021. The Board engaged in discussion and a series of voting rounds to select the following: President-elect: Valentina Greco, PhD; Vice President-elect: Aimee Payne, MD/PhD; and Resident Board Rep: Leandra Barnes, MD/PhD.
        The Committee also asked the Board to consider assigning the other outstanding trainee candidates to standing and ad-hoc committees to give them an inside look at the Society for Investigative Dermatology (SID) governance and program development processes and provide them with access to the community.
        To implement the recently approved charges directed to the nominations committee for selecting Board members, the group reviewed and approved the slate of Director candidates. It was noted that four of the candidates were Industry representatives. There is no formal designation of an industry member of the board, but current directors felt that the SID had benefitted from their counsel in the past. There was some discussion about whether to change the bylaws to add the requirement for an industry member. It was decided that the bylaws should stand as written, but if an industry candidate were not selected, the Board could merely recruit an ex-officio industry consultant to advise the Board.
        A slate of seven candidates was presented: Cassandra Quave, PhD; My Mahoney, PhD; Maksim Plikus, PhD; Hans Hofland, PhD; William Ju, MD; Edward Hsia, PhD; and Lloyd Miller, MD/PhD. A motion was made to accept the entire slate, seconded, and approved.
        These finalists will be contacted and congratulated as nominees for a Board director slot. Those who accept will be carried forward for an online vote by SID members in the spring, and an official vote will occur in conjunction with the SID business meeting, which will be held during the 2021 virtual SID meeting.

         Standing Committee Openings

        Nicole Ward, Secretary-Treasurer, began the voting process to fill the vacancies in SID standing committees. The Board deliberated the candidates for the various committees and cast a series of votes, ending in the approval of the following:
        • 1.
          Audit Committee: Aimee Payne, MD/PhD, Dan Kaplan, MD/PhD
        • 2.
          Executive Committee: Andrew Kowalczyk, PhD
        • 3.
          Committee on Finance: Luis Garza, MD/PhD (Board Rep);
        • 4.
          Committee on Nominations 3-year term: List of candidates will be sent to the Board for electronic voting. The top five will be selected for a 3-year term.
        • 5.
          Committee on Honorary Members 3-year term: Kevin Cooper, MD
        • 6.
          Committee on Scientific Programs 3 five-year terms (2021‒2026): Jaehyuk Choi, MD/PhD; Heidi Kong, MD; and Junko Takeshita, MD/PhD.
        • 7.
          Committee on Education-2 five-year terms (2021‒2026): Lilit Garibyan, MD/PhD and David Woodley, MD
        • 8.
          Committee on Membership 2021‒2024: Fiona Kuo, PhD; Yi Zhao, MD/PhD.

         Educational Programs

        Jim Rumsey, Chief Operating Officer, and Dr. Fairley reviewed the names of those selected for named and state-of-the-art lectures for the 2021 meeting, timeframes associated with the abstract submission (which opens on October 21), deadline (January 5, 2021), and initial and final reviews. The final list of abstract categories was also provided. To make the meeting more innovative, they were exploring the possibility of featuring named lectures in a “Ted Talk” fashion.
        The program and draft meeting grid were presented and discussed; it included approximately 3 hours of live sessions each day from Wednesday 5 May through Sunday 9 May. Some Board members felt that many attendees would want longer live sessions on fewer days and others expressed concern that even 3 hours of live programming may cause “Zoom fatigue.” It was agreed that a survey be deployed to poll SID members on their career stage, preferences for the duration of live sessions, time zone, and on which days the meeting should take place.
        Mr. Rumsey reviewed the dates and future sites for meetings. To release the SID from the 2021 Chicago contract and shift to a virtual meeting, he had negotiated holding the SID meeting at the same venue, the Hilton Chicago, from 13–16 May 2026. This was done without any financial penalty to the SID.

         Finance

        Mr. Rumsey presented the Finance report prepared by the Committee Chair, Louis Falo, to the Board, which detailed items of note for fiscal year (FY) 2020 YTD budget and the surplus projected. The Board reviewed the committee’s assessment and recommendation of the proposed 2021 SID operating budget that estimated a modest surplus. The Board deliberated the proposed budget, and a motion was made to approve the proposed FY 2021 operating budget. The motion was seconded and unanimously approved.

         Development/Fundraising

        Becky Minnillo, Chief Program, Communications, and Development Officer, spoke to the group about development efforts on behalf of the SID for the year, including plans for fundraising efforts for 2021—not expected to be nearly as high as prior years due to the transition to a virtual meeting that will charge registration fees. Efforts will focus on multiple technology-based sponsorship opportunities and expanding corporate membership.

         Other

        Dr. Fairley informed the Board that her presidential initiative, “Networking Circles” was underway, and that over 80 people had applied, including a diverse group of both mentors and mentees. She is working with Dr. Minnillo to assign the circles by themes, develop the structure and process for getting the groups going.
        The planned series of virtual programs is still in early development. Dr. Kowalczyk has volunteered to lead the effort and will coordinate with the committee on education cochairs to develop themes and a schedule.
        Other topics that were briefly touched on included updates on upcoming changes to the SID website, more frequency in newsletter communications, potential changes to committee charges, and updates regarding the International SID.
        With no further business to discuss, a motion to adjourn was made, seconded, and unanimously approved.
        Prepared by Becky Minnillo on 22 October 2020.
        Table 1Attendance at Annual Meeting
        YearAttendees
        1988600
        19891,200
        1990930
        1991960
        19921,058
        19931,131
        19941,217
        19951,282
        19961,316
        19971,206
        19981,911
        19991,230
        20001,159
        20011,368
        20021,266
        20031,898
        20041,554
        20051,475
        20061,530
        20071,443
        20081,528
        20091,142
        20101,346
        20111,350
        20121,339
        20132,400
        20141,208
        20151,127
        20161,281
        20171,606
        20182,332
        20191,641
        20201,631
        Table 2Membership, 2000-2020
        Type200020012002200320042005200620072008200920102011201220132014201520162017201820192020
        Active1213120111781167118811501146115210541033105011181172943105810381012114910511062544
        Patron19721921421120520722127626622812689756067636560646962
        Individual303337242900000000000000044
        Corporate12107113334222232243332
        ESDR/SID424041394142466667716566667052565666666766
        Residents/Fellows100117109108130110120150146141123123106318199180267314251624366
        Honorary474747504648474748535848535759656062687073
        Life Member12242421242830303112295347373238394041415
        Total membership1,6531,6911,6571,6211,6641,5881,6131,7241,6161,5401,4531,4991,5211,4881,4691,4421,5031,6941,5441,9361,162
        Abbreviations: ESDR, European Society for Dermatological Research; SID, Soceity of Investigative Dermatology.
        Table 3Balance Sheet as of December, 2020 (Un-Audited)
        Income2020
         Dues$213,350
         Registration fees$0
         Journal income$1,716,646
         Other income$724,141
         Contributions$0
        Total income$2,654,136
        Expenses
         SID office$358,277
         JID office$987,527
         Annual Meeting$399,415
         Committees$116,659
         Other expenses$588,638
        Total expenses$2,450,516
        Net income (loss)$203,621
        Abbreviations: JID, Journal of Investigative Dermatology; SID, Soceity of Investigative Dermatology.
        Table 4Income Statement for Year Ending December 31, 2019
        The Society for Investigative Dermatology

        Statement of Financial Position

        December 31, 2019
        2019
        Assets
         Cash and cash equivalents$4,277,120
         Investments in marketable securities$3,623,566
         Royalty/Mgmt. fees receivable$260,883
         Prepaid expenses$135,162
         Deposits$0
         Property and equipment net of accumulated depreciation$0
        Total assets$8,296,731
        Liabilities
         Unearned revenue$140,714
         Accounts payable$364,608
        Net assets
         Unrestricted$5,102,959
         Temporarily restricted$2,688,450
        Net assets$7,791,409
        Total liabilities and net assets$8,296,731
        Table 5Current Cash Assets, December 31, 2020 (Un-Audited)
        20102011201220132014201520162017201820192020
        Operating fund
        Board directed funds.
        $837,604$1,061,683$1,307,527$742,597$1,185,461$1,983,537$2,306,679$3,246,295$3,899,212$3,478,855$3,972,627
        Named funds
         Beerman
        Board directed funds.
        $70,753$69,211$76,119$87,183$94,747$91,645$101,020$121,556$115,366$148,340$172,156
         Blank
        Board directed funds.
        $61,481$60,143$68,196$80,093$87,017$79,895$81,069$97,414$92,410$118,897$137,787
         Montagna
        Board directed funds.
        $76,570$74,388$82,987$101,064$111,262$109,698$121,018$146,059$138,728$178,883$207,681
         Kanof
        Board directed funds.
        $61,657$54,202$59,645$76,338$82,031$82,586$92,646$111,838$106,262$139,467$161,931
         Katz
        Restricted funds.
        $0$0$0$0$0$0$0$0$0$294,245$369,845
         Stone
        Board directed funds.
        $89,157$90,179$92,513$91,256$90,508$87,523$89,774$92,272$90,103$96,913$104,897
         Farber
        Restricted funds.
        $267,437$254,786$291,930$379,712$434,915$438,825$424,312$511,141$458,663$580,511$677,510
         Kligman/Frost$53,161$53,335$45,009$45,069$45,141$45,207$45,252$45,297$45,343$386$0
        Misc.
        Board directed funds.
        $19,150$66,622$85,346$191,996$224,382$220,993$233,176$247,503$633,150$654,941$672,556
        JID Fund
        Board directed funds.
        $660,449$663,469$767,461$1,005,776$1,143,094$1,139,349$1,243,549$1,502,695$1,412,449$1,839,613$2,139,332
        Total$2,197,418$2,448,016$2,876,734$2,801,085$3,498,558$4,279,257$4,738,496$6,122,071$6,991,686$7,531,051$8,616,322
        Abbreviation: JID, Journal of Investigative Dermatology.
        1 Board directed funds.
        2 Restricted funds.